• uniQure’s Huntington’s Disease Trial Shows Promising Results

    Oct 16 | Bio-IT World | Last month, uniQure announced promising results from their Phase I/II study of AMT-130, the company’s gene therapy to treat Huntington’s disease. A participant pool of 29 patients in the early stages of Huntington’s disease was categorized into two groups—low-dose and high-dose—and compared to a control group of 1,600 untreated Huntington’s patients at similar disease stages. More

  • New Immunotherapy Approach Hits the Sweet Spot with Solid Tumors

    Oct 15 | Bio-IT World | Glycans, the complex sugar chains found at abnormally high levels on the surface of cancer cells, have historically been difficult to target effectively with traditional antibody therapies. One of the biggest reasons is that T cells can’t present glycans to B cells so they can make antibodies that bind strongly and stably to the target antigen. More

  • TOR Inhibitors Could One Day Be Multi-Purpose Healthspan Drugs

    Oct 14 | Bio-IT World | The Target of Rapamycin (TOR) signaling pathway is a prime target for therapeutic development, since its dysregulation is implicated in promoting aging and a range of age-related diseases. By inhibiting TOR, the prescription medication rapamycin has been successfully used to prevent organ transplant rejection and treat certain cancers, but its use for anti-aging purposes in healthy individuals has yet to be approved by the Food and Drug Administration (FDA). More

  • Boltz Upgrade: Recursion Researchers Release Pipeline Combining AI Binding Model with Absolute Binding Free Energies

    Oct 10 | Bio-IT World | Researchers from Recursion are further developing their work on protein-ligand docking with a new digital tool: the Boltz-ABFE pipeline. This summer, with researchers from MIT, Recursion researchers released Boltz-2, an updated artificial intelligence model that can predict protein structure and binding affinity. More

  • Former Musician Casey McPherson Tackles Rare Disease Cures Through Biotech

    Oct 10 | Bio-IT World | Over 10,000 rare diseases affect millions worldwide, yet fewer than 5% have treatments. Musician-turned-biotech founder Casey McPherson is rewriting the playbook for rare disease research and drug development, which he discusses in the latest episode of Trends from the Trenches. More

  • Pistoia Alliance Tackles Agentic AI in Pharmaceutical Research

    Oct 02 | Bio-IT World | The Pistoia Alliance has launched a new initiative to advance the safe adoption of agentic AI. The initiative sits under the Alliance’s strategic priority to Harness AI to Expedite R&D and alongside its AI/ML Community of Experts, which is actively seeking further funding to continue supporting responsible AI adoption across the industry. More

  • Call for Entries: 2026 Bio-IT World Innovative Practices Award

    Oct 01 | Bio-IT World | Bio-IT World is now accepting entries for the 2026 Innovative Practices Awards, a competition designed to recognize the most exciting partnerships and projects pushing the life sciences industry forward. The deadline for entry is March 2, 2026, and the $300 application fee will be waived for entrants who meet the early submission deadline of January 30, 2026. More

  • Quest is on for a ‘Super-Tolerable’ Weight-Loss Drug

    Sep 30 | Bio-IT World | Coming up with a medication that produces weight loss or prevents weight gain without any of the miserable side effects associated with top-selling drugs like Ozempic and Zepbound is the holy grail of every pharma company in the obesity space. About 70% of Americans are now considered overweight or obese, but relatively few of them are currently being treated with the otherwise popular weight-loss medications due in large part to side effects associated with the glucagon-like peptide-1 (GLP-1) pathway they activate in the gut and brain to achieve their effects. More

  • New Classification System Tackling Recurrent Ovarian Cancer

    Sep 26 | Bio-IT World | A new classification system for recurrent ovarian cancer was developed by scientists at Lausanne University Hospital and the Ludwig Institute for Cancer Research. The system combines genomic sequencing with immune profiling to stratify patients into four immunologic subgroups, laying the groundwork for personalized therapies that could extend survival. More

  • NIST Collaboration for “Living” Reference Material, Pistoia Alliance’s New Agentic AI Initiative, More

    Sep 25 | Bio-IT World | National Institute of Standards and Technology (NIST) has collaborated with biotech company MilliporeSigma and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to create a “living” reference material; the Pistoia Alliance plans to establish a new initiative to advance the safe adoption of agentic AI; and more. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight
Trends from the Trenches

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders. BioTeam co-founder Stan Gloss brings years of industry experience in science, data, and technology to conversations exploring what is driving data and discovery, and what’s coming next.
Listen today!